Causal multi-modal AI predicts who benefits from chemotherapy — and who will not
Ataraxis lands $20.4 million Series A to accelerate clinical deployment of AI precision medicine
Empowering physicians with advanced multi-modal tools to improve treatment selection and patient outcomes.